Skip to main content
ABEO
NASDAQ Life Sciences

Abeona Reports First ZEVASKYN Revenue, Expands Pipeline with New Oncology Asset, and Maintains 12-Month Cash Runway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$5.98
Mkt Cap
$324.038M
52W Low
$4
52W High
$7.54
52W Position info
50% above low
Off High info
21% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

ABEO sits 50% above its 52-week low of $4.

Summary

Abeona Therapeutics reported its first product revenue of $8.7 million from ZEVASKYN in Q1 2026, alongside a strategic pipeline expansion with the in-licensing of ABO-701 for prostate cancer, despite an increased net loss of $17.1 million. The company maintains sufficient liquidity for at least the next 12 months.


Key Events · Earnings and Guidance · ABEO

  • First Product Revenue Reported

    Abeona Therapeutics reported $8.7 million in net product revenue for Q1 2026 from ZEVASKYN, marking its first quarter of commercial sales following FDA approval in April 2025.

  • Net Loss Widens Amid Commercialization Efforts

    Net loss increased to $17.1 million in Q1 2026, up from $12.0 million in Q1 2025. This was primarily driven by a 99% increase in selling, general, and administrative expenses to $19.5 million, reflecting costs associated with ZEVASKYN's commercial launch.

  • Strategic Pipeline Expansion and Prioritization

    The company in-licensed ABO-701, a novel T-cell therapy for prostate cancer, with a $7.0 million upfront payment and plans for an IND filing in H2 2027. Concurrently, Abeona deprioritized its in-house ophthalmology programs and terminated the CLN1 disease program.

  • Liquidity Position and Cash Runway

    Abeona ended Q1 2026 with $168.3 million in cash, cash equivalents, and short-term investments, stating these resources are sufficient to fund operations for at least the next 12 months.


Analysis · ABEO · Life Sciences

This quarterly report provides the detailed financial performance following Abeona's transition to a commercial-stage company. The generation of $8.7 million in product revenue from ZEVASKYN is a significant milestone, validating its commercial launch. While the net loss increased to $17.1 million, this is largely attributable to increased selling, general, and administrative expenses necessary for commercialization. The strategic decision to acquire ABO-701, a new oncology asset, and streamline other pipeline programs indicates a focused development strategy. The company's statement of having over 12 months of cash runway provides crucial financial stability for its ongoing commercial and development efforts. The 10b5-1 plans from the CFO and a director represent modest, pre-planned insider sales.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ABEO was trading at $5.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $324M. The 52-week trading range was $4.00 to $7.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ABEO - Latest Insights

ABEO
Nov 09, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.52
Real-time Price: $2.42 info
Change: -$0.100 (-4%) info
Market Cap: $140.01M info
ABEO
Nov 09, 2026, 11:06 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $2.62
Real-time Price: $2.42 info
Change: -$0.195 (-7%) info
Market Cap: $140.01M info
ABEO
Nov 09, 2026, 6:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.01
Real-time Price: $2.42 info
Change: -$1.59 (-40%) info
Market Cap: $140.01M info
ABEO
Nov 09, 2026, 6:35 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $4.01
Real-time Price: $2.42 info
Change: -$1.59 (-40%) info
Market Cap: $140.01M info
ABEO
Nov 09, 2026, 6:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.18
Real-time Price: $2.42 info
Change: -$1.76 (-42%) info
Market Cap: $140.01M info